[1] Honoré N, van Marcke C, Galot R, et al. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.Ann Oncol, 2023,34(12):1175-1186. [2] Lina Z ,Liping J ,Yunhe L , et al. Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma.ClinTranslat Med, 2022,12(4):e793-e793. [3] Ahn KS, Kang KJ. Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation? Clin Mol Hepatol, 2019,25(4):354-359. [4] 王晓刚,童钟,宇汝胜,等. 肝细胞癌患者血清中微小RNA-432、微小RNA-30b、微小RNA-764水平. 中华实验外科杂志,2020,37(10):1887-1889. [5] van der Pol CB, McInnes MDF, Salameh JP, et al. CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: individual patient data meta-analysis. Radiology, 2022,302(2):326-335. [6] Lyshchik A ,Fetzer TD ,Kono Y , et al. Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024.Radiology, 2024,311(2):e232369-e232369. [7] Hu J, Burrowes DP, Caine BA, et al. Nodules identified on surveillance ultrasound for HCC: CEUS or MRI as the initial test? J Ultrasound Med, 2023,42(6):1181-1190. [8] Bansal S, Lu F, Frehlich L, et al. A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS. Abdom Radiol (NY), 2022,47(2):618-629. [9] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版).中华肝脏病杂志,2015,23(5):321-327. [10] Alessandro F ,Navya D ,Christopher B , et al. Use of percutaneous imaging-guided biopsy for liver imaging and reporting data system (LI-RADS) observations: a retrospective study from two liver transplant centers.Curr Probl Diagn Radiol, 2023,53(2):235-238. [11] Connor K ,Manjiri D ,Alicia C , et al.Quantification ofhepatocellular carcinoma vascular dynamics with contrast-enhanced ultrasound for LI-RADS implementation.Invest Radiol,2023,59(4):337-344. [12] Haneyeh S ,Jason B ,Jane P B , et al.Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma.Abdom Radiol (New York),2023,48(12):3696-3702. [13] Maria SB ,Codruţa E G ,Carmen N , et al. Quantitative time intensity curve analysis of contrast-enhanced ultrasound (CEUS) examinations for the assessment of focal liver lesions.Med Ultrasonogr, 2023,26(1):63-71. [14] Peng H ,Qin S ,Xiaoyan N , et al. Subcentimeter hepatocellular carcinoma (HCC) on gadoxetic-acid-enhanced MRI: less frequent typical imaging features compared to 1-2 cm HCC but better prognosis after surgical resection.Abdom Radiol (New York), 2023,48(11):3391-3400. [15] Ding J, Long L, Zhang X, et al. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol, 2021,31(2):847-854. [16] 梁雪,潘金彬,丁建民,等. 超声造影LI-RADS与增强CT/MRI LI-RADS对肝微小病灶分类的一致性及差异性研究. 中华超声影像学杂志,2021,30(11):938-943. [17] 周燕,李丹,龙磊,等. 混合型肝癌的增强模式分析及超声造影联合增强CT/MRI及肿瘤标志物的诊断价值. 中华超声影像学杂志,2020,29(9):754-760. [18] Auer TA, Halskov S, Fehrenbach U, et al. Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5th edition of the world health organization classification.Eur Radiol, 2023,33(10):6902-6915. [19] Vietti Violi N, Taouli B. Abbreviated MRI for HCC surveillance: is it ready for clinical use?Eur Radiol, 2020,30(8):4147-4149. [20] Eisenbrey JR, Gabriel H, Savsani E , et al.Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.Abdom Radiol (NY), 2021,46(8):3579-3595. |